AR and early-onset autosomal dominant Alzheimer disease: Thus chaperone functionality in Alzheimer’s disease and the possibility of AR-12 or analogues of AR-12 being developed as a therapeutic for this disorder should be considered if supported by appropriate in vivo preclinical models.